Literature DB >> 27120749

Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.

Drew J B Kurtzman1, Natalie A Wright1, Janice Lin1, Alisa N Femia1, Joseph F Merola1, Mital Patel1, Ruth Ann Vleugels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27120749     DOI： 10.1001/jamadermatol.2016.0866

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  28 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 2.  The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.

Authors:  Qin Xu; Xuexiao Jin; Yu Jiang; Xin Dang; Yongmei Han
Journal:  Clin Rheumatol       Date:  2020-07-16       Impact factor: 2.980

Review 3.  Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.

Authors:  Kristen L Chen; Majid Zeidi; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2019-08-31       Impact factor: 4.592

Review 4.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-11-06       Impact factor: 84.694

5.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

Review 6.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

7.  [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment].

Authors:  J Hornig; T Weinhage; L H Schmidt; B Buerke; U Schneider; H Pavenstädt; H Becker; G Gabriëls
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

8.  Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.

Authors:  Sara Sabbagh; Adriana Almeida de Jesus; SuJin Hwang; Hye Sun Kuehn; Hanna Kim; Lawrence Jung; Ruy Carrasco; Sergio Rosenzweig; Raphaela Goldbach-Mansky; Lisa G Rider
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

Review 9.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 10.  The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.

Authors:  S Ahmed; K L Chen; V P Werth
Journal:  Semin Arthritis Rheum       Date:  2020-01-11       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.